Fox Run Management L.L.C. Purchases Shares of 19,117 ADMA Biologics, Inc. (NASDAQ:ADMA)

Fox Run Management L.L.C. purchased a new stake in shares of ADMA Biologics, Inc. (NASDAQ:ADMA) in the fourth quarter, HoldingsChannel reports. The institutional investor purchased 19,117 shares of the biotechnology company’s stock, valued at approximately $328,000.

Several other hedge funds and other institutional investors also recently modified their holdings of ADMA. Natixis Advisors LLC purchased a new stake in ADMA Biologics in the third quarter valued at approximately $345,000. Mutual of America Capital Management LLC bought a new position in shares of ADMA Biologics in the 3rd quarter worth $701,000. Intech Investment Management LLC purchased a new stake in shares of ADMA Biologics during the 3rd quarter valued at $1,242,000. Charles Schwab Investment Management Inc. lifted its holdings in shares of ADMA Biologics by 11.6% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 2,401,533 shares of the biotechnology company’s stock worth $48,007,000 after acquiring an additional 249,412 shares during the last quarter. Finally, Citigroup Inc. grew its position in ADMA Biologics by 251.7% in the third quarter. Citigroup Inc. now owns 387,226 shares of the biotechnology company’s stock worth $7,741,000 after acquiring an additional 277,138 shares in the last quarter. Hedge funds and other institutional investors own 75.68% of the company’s stock.

ADMA Biologics Price Performance

Shares of ADMA Biologics stock opened at $19.70 on Thursday. The company has a debt-to-equity ratio of 0.48, a quick ratio of 3.26 and a current ratio of 7.09. ADMA Biologics, Inc. has a 52-week low of $5.90 and a 52-week high of $23.64. The company has a fifty day moving average of $16.97 and a 200-day moving average of $18.11. The stock has a market capitalization of $4.66 billion, a price-to-earnings ratio of 70.36 and a beta of 0.60.

Analyst Ratings Changes

Separately, Cantor Fitzgerald restated an “overweight” rating and set a $25.00 price target on shares of ADMA Biologics in a research report on Tuesday, March 4th.

About ADMA Biologics

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.